We did it! We recorded a live teaser and a now a timely Best of ESMO 2025 episode... Part 1 of 2!

In this episode, hear host James Larkin's favorite childhood vacations (dry skiing, upside down toothbrush hills and Mallorca... so privileged)

James & Sapna focus on the 3 neoadjuvant melanoma presentations at ESMO 2025 and take a deep dive in to the results and questions raised for clinic on Monday.

Enjoy this brief behind-the-scenes discussion from ESMO 2025 where we plan our upcoming Best of ESMO episode

#ESMO25 #ESMO26 @melanomamatterspod

Enjoy this trailer of Episode 72 - James takes a test!

For the record, we recorded this episode in February 2024 :) better late than never to get it published!

In this episode, James has no idea what he's in for. Sapna quizzes James on new drug approvals in hematology & oncology in the year 2024 to see if he can guess the cancer type and mechanism of action.

Summary

In this episode, hosts James Larkin & Sapna Patel discuss the Women in Melanoma Conference, highlighting its role in fostering networking and collaboration among female oncologists. They reflect on the evolution of the conference, its impact on participants, and the importance of addressing women's issues in oncology. The discussion also touches on the potential for expanding the initiative beyond the U.S. and the value of creating a supportive community for women in the medical field.

James reveals a lack of stupid human tricks, Sapna reports on her skill with napkin lipstick blots, and the two fawn over word clouds in the shape of the female form (e.g. Figure 1). Moral of the story? Don't tease, and James is the bigger geek... all around

Keywords

melanoma, women in oncology, networking, collaboration, medical conference, women empowerment, survivorship, oncology research, patient care, medical community

Takeaways

The Women in Melanoma Conference was initiated to address the lack of female representation in oncology meetings.

Networking and collaboration are crucial for professional growth in oncology.

The conference has evolved to include a broader range of topics relevant to women in the medical field.

Participants have expressed feelings of camaraderie and support through the conference.

The initiative has led to successful collaborations and publications among attendees.

There is potential for expanding the Women in Melanoma initiative internationally.

The conference addresses both professional and personal challenges faced by women in oncology.

Role-playing exercises have been beneficial for participants in handling difficult conversations.

The conference serves as a platform for discussing patient-centered care and survivorship.

The success of the initiative may inspire similar programs in other medical specialties.

Sound Bites

"It's been a lovely forum."

"There's no reason this has to stay U.S."

"We captured lightning in a bottle here."

Chapters

00:00 Introduction and Icebreakers

02:53 Val Guild & the Inception of WIM

06:53 Networking and Collaboration in Oncology

10:45 Expanding the Women in Melanoma Initiative

14:26 Figure 1. Word Cloud

19:07 Fact Check (there are 2 Fact Checks!)

29:57 Fact Check Within a Fact Check

You wanted it, we gave it... best of ASCO ...colon...2025 :D

In this episode, hosts James and Sapna discuss the key highlights from ASCO 2025, focusing on significant abstracts related to melanoma treatment. They delve into the implications of adrenal insufficiency, the 5 year, final results of Lifileucel, and the ongoing debate between neoadjuvant and adjuvant therapies. The conversation also explores the role of IL-6 in treatment efficacy and the importance of understanding sentinel lymph node positivity. The hosts emphasize the need for innovative clinical trial designs to adapt to emerging data and improve patient outcomes.

Keywords

ASCO 2025, melanoma, neoadjuvant therapy, adrenal insufficiency, lifileucel, immunotherapy, clinical trials, IL-6, treatment outcomes, cancer research

Chapters

00:00 Introduction and Overview of ASCO 2025

03:16 DoorDash!

05:43 Key Highlights from ASCO 2025

08:29 Lifileucel and Its Impact on Treatment

10:53 Long-term Outcomes and Toxicity Considerations

15:49 Exploring Treatment Efficacy in Refractory Populations

17:41 Neoadjuvant and Adjuvant Therapies: A Comparative Analysis

21:07 Investigating GM-CSF's Role in Mitigating Toxicity

22:36 RELA 098: Insights and Implications

25:37 Understanding Sentinel Lymph Node Positivity in Melanoma

26:34 Future Directions in Neoadjuvant Therapy Research

36:18 Fact Check

38:17 Discussion on IPI GM-CSF and Adrenal Insufficiency

42:09 Impact of Adrenal Insufficiency on Patients

45:06 Future Directions in Neoadjuvant Trials

47:26 Wrap-Up and Reflections

Summary

In this episode, Sapna Patel and James Larkin engage with Monty Pal from City of Hope, discussing his unique journey into oncology, the significance of the microbiome in cancer treatment, and the impact of diet and lifestyle on patient outcomes. They explore current research, including clinical trials involving fecal microbiome transplants and the potential of specific bacteria to enhance immunotherapy effectiveness. The conversation highlights the evolving landscape of cancer treatment and the promising future of microbiome research in oncology.

Keywords

oncology, microbiome, cancer treatment, immunotherapy, diet, clinical trials, kidney cancer, melanoma, fecal microbiome transplant, City of Hope

Takeaways

Monty Pal started college at the age of 13, showcasing an unconventional path to medicine.

His journey into oncology was influenced by a pivotal decision to switch from engineering to medicine

Monty has significantly contributed to the growth of the GU oncology program at City of Hope.

The microbiome plays a crucial role in predicting patient outcomes and side effects in cancer treatment.

Dietary fiber intake has been linked to improved clinical outcomes in melanoma patients receiving immunotherapy.

Random probiotics may not be beneficial and could even be harmful to patients.

Research indicates that specific bacteria can enhance the effectiveness of immunotherapy.

The future of cancer treatment may involve turning cold tumors into hot tumors using microbiome interventions.

Titles

The Journey of Monty Pal: From Prodigy to Oncologist

Microbiome and Cancer: Turd Burglars to Treatment

Sound Bites

"I started college when I was 13."

"Fiber seems to be somewhat interesting."

Chapters

00:00 Introduction and Introduction of Monty Pal from City of Hope

01:42 Monty's Journey to Medicine

05:19 GU Oncology at City of Hope

10:28 The Microbiome: A New Frontier in Oncology

14:52 Microbiome Research and Clinical Outcomes

19:21 Lifestyle Factors and the Microbiome

23:51 Intervention Strategies: Fecal Microbiome Transplant and Beyond

24:35 South Park Episode: Turd Burglars

29:58 An Upcoming SWOG trial

32:48 Fact Check

Summary

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss the Godfather 15 trial, focusing on the neutralizing GDF 15 antibody and its implications in overcoming PD-1 and anti-PD-L1 resistance in solid tumors. They explore the background of GDF-15, its role in immune suppression, and the trial's methodology, including safety and efficacy results. The conversation also touches on the future directions of GDF-15 antibody trials and the importance of understanding treatment resistance in cancer therapy.

Keywords

Melanoma, GDF-15, Godfather 15 trial, immunotherapy, cancer research, PD-1, antibody therapy, clinical trials, immune suppression, treatment resistance

Takeaways

The Godfather 15 trial focuses on neutralizing GDF-15 antibody.

GDF-15 is linked to immune suppression in tumors.

The trial is a phase 1/2 study with multiple dose levels.

Understanding treatment resistance is key in cancer research.

The importance of defining refractory cohorts in trials.

Biological proof of concept is essential in early studies.

Future trials should focus on specific patient populations.

Sound bites

"This is a phase 1/2 study"

"This is the biology we're targeting"

"I think this is obviously just a first step"

Chapters

00:00 Introduction to the Godfather 15 Trial

07:48 Understanding GDF-15 and Its Role in Cancer

11:48 Exploring the Study Design and Methodology

18:42 Results and Efficacy of the GDF-15 Antibody

25:09 Future Directions and Closing Thoughts

Summary

In this conversation, James Larkin and Sapna Patel discuss the consensus definitions for resistance to immune checkpoint inhibitors, focusing on a recent paper from the Journal of Immunotherapy of Cancer. They explore the complexities of primary and secondary resistance, the importance of defining these terms for clinical trials, and the challenges in trial design and control arms. The discussion emphasizes the need for clear definitions to improve patient outcomes and guide future research in oncology.

Keywords

immune checkpoint inhibitors, cancer treatment, resistance, clinical trials, melanoma, PD-1, adjuvant therapy, response rate, tumor sensitivity, oncology

Takeaways

Resistance to immune checkpoint inhibitors is a major challenge in melanoma treatment.

Primary resistance occurs when there is no benefit from treatment, while secondary resistance follows initial benefit.

Defining resistance is crucial for clinical trials and understanding patient populations.

The duration of drug exposure is key in determining resistance types.

Clinical trial design must consider the expectations of efficacy in control arms.

Investigators should be cautious about the definitions of patient populations in trials.

Response rates of 15-20% are considered significant for primary resistance.

Secondary resistance may show higher response rates due to residual sensitivity.

Clear definitions help in layering data for future research.

Collaboration among clinicians, industry, and regulatory bodies is essential for advancing cancer treatment.

Sound Bites

"It's probably the biggest challenge we now have in clinic."

"There's something in the middle."

"I think that's where we might need to be there."

Chapters

00:00 Introduction to Immune Checkpoint Inhibitors and Resistance

08:08 Understanding Resistance: Definitions and Scenarios

14:47 Primary vs. Secondary Resistance in Clinical Trials

22:00 Trial Design and Control Arms in Immunotherapy

30:36 Conclusions and Future Directions

33:28 outro fade long expo.mp4

Summary

In this episode of Melanoma Matters, James Larkin and Sapna Patel discuss the recent advancements in understanding and treating cancer cachexia, particularly focusing on the drug ponsegramab. They explore the implications of cachexia across different cancer types, the role of cytokine GDF-15, and the importance of nutrition and physical activity in managing cachexia. They opine on body weight and protein, as per usual.

Keywords

cancer cachexia, ponsegramab, GDF-15, treatment options, nutrition, clinical trials, melanoma, kidney cancer, pancreatic cancer, weight gain

Takeaways

Cancer cachexia is a significant issue in various cancers.

Ponsegramab shows promise in treating cachexia with meaningful weight gain.

GDF15 is a key cytokine elevated in cancer cachexia.

Historical treatments for cachexia have included progestins, but newer options are emerging.

Nutrition and physical activity are crucial in managing cachexia.

Collaboration between academia and industry is vital for drug development.

The study of Ponsegramab was conducted across multiple institutions.

Cachexia management requires a multifactorial approach.

Clinical trials must consider the contributions of all stakeholders.

Future research is needed to optimize treatment for cachexia.

Sound Bites

"This is about cancer cachexia."

"We do see the sarcopenia."

"Doctors have known about this for 2,000 years."

Chapters

00:00 Introduction to Cancer Cachexia

02:43 Understanding Cachexia in Different Cancers

06:41 The Role of GDF-15 in Cancer Cachexia

10:39 Clinical Trial Insights on Ponsegramab

18:37 Exploring Treatment Implications and Future Directions

24:36 Authorship and Collaboration in Cancer Research

32:47 Fact Check

33:36 Discussion on Cancer Cachexia and Bonsegramab

38:14 Historical Context of Treatment in Kidney Cancer

42:28 Current Guidelines and Future Directions for Cachexia Treatment